Nuclear membranes GPCRs: Implication in cardiovascular health and diseases

Current Vascular Pharmacology

Volumn 12, Issue 2, 2014, Pages 215-222

  Bkaily, Ghassan ^a   Al Khoury, Johny ^a   Jacques, Danielle ^a  

^a UNIVERSITÉ DE SHERBROOKE   (Canada)

Author keywords

Angiotensin II; Endothelin 1; GPCR; Neuropeptide Y; Nuclear receptors; PAF; Prostaglandins; VIP receptors

Indexed keywords

ANGIOTENSIN; CYCLIC AMP; ENDOTHELIN 1; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FOCAL ADHESION KINASE 2; G PROTEIN COUPLED RECEPTOR; GUANOSINE DIPHOSPHATE; GUANOSINE TRIPHOSPHATASE; JANUS KINASE; NEUROPEPTIDE Y; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROSTAGLANDIN; PROTEIN KINASE C; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; CELL FUNCTION; ENZYME ACTIVITY; HOMEOSTASIS AND REGULATION; HUMAN; PATHOGENESIS; PHYSIOLOGY; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; VASCULAR BIOLOGY;

EID: 84922435193     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/1570161112666140226120837     Document Type: Article

References (78)

1. [1] Lu D, Yang H, Shaw, G, Raizada MK. Angiotensin II-induced nuclear targeting of the angiotensin type-1 (AT1) receptor in brain neurons. Endocrinology 1998; 139: 365-75.
2. [2] Bkaily G. Ionic Channels in vascular smooth muscle. G Bkaily Ed. Molecular Biology Intelligence Unit: Austin 1994.
3. [3] Bkaily G, Pothier P, D’Orleans-Juste P, et al. The use of confocal microscopy in the investigation of cell structure and function in the heart, vascular endothelium and smooth muscle cells. Mol Cell Biochem 1997; 172: 171-94.
4. [4] Bkaily G, Choufani S, Hassan G, El-Bizri, N Jacques, D D’Orleans-Juste, P. Presence of functional endothelin-1 receptors in nuclear membranes of human aortic vascular smooth muscle cells. J Cardiovasc Pharmacol 2000; 36: S414-17.
5. [5] Bkaily G, Sleiman S, Stephan J, et al. Angiotensin II AT1 receptor internalization, translocation and de novo synthesis modulate cytosolic and nuclear calcium in human vascular smooth muscle cells. Can J Physiol Pharmacol 2003; 81(3): 274-87.
6. [6] Bkaily G, Avedanian L, Al-Khoury J, et al. Nuclear membrane receptors for ET-1 in cardiovascular function. Am J Physiol Integr Comp Physiol 2011; 300: R251-63.
7. [7] Avedanian L, Jacques D, Bkaily G. Presence of tubular and reticu-lar structures in the nucleus of human vascular smooth muscle cells. J Mol Cell Cardiol 2011; 50: 175-86.
8. [8] Bkaily G, Avedanian L, Al-Khoury J, Ahmarani L, Perreault C, Jacques D. Receptors and ionic transporters in nuclear membranes: new targets for therapeutical pharmacological interventions. Can J Physiol Pharmacol 2012; 90(8): 953-65.
9. [9] Boivin B, Chevalier D, Villeneuve LR, Rousseau E, Allen, BG. Functional endothelin receptors are present on nuclei in cardiac ventricular myocytes. J Biol Chem 2003; 278: 29153-63.
10. [10] Boivin B, Lavoie C, Vaniotis G, et al. Functional beta-adrenergic receptor signalling on nuclear membranes in adult rat and mouse ventricular cardiomyocytes. Cardiovasc Res 2006;71(1):69-78.
11. [11] Gobeil F Jr, Dumont I, Marrache AM, et al. Regulation of eNOS expression in brain endothelial cells by perinuclear EP3 receptors. Circ Res 2002; 90: 682-89.
12. [12] Gobeil F, Fortier A, Zhu T, et al. G-protein-coupled receptors signalling at the cell nucleus: an emerging paradigm. Can J Physiol Pharmacol 2006; 84(3-4): 287-97.
13. [13] Jacques D, Descorbeth M, Abdel-Samad D, Provost C, Perreault C, Jules F. The distribution and density of ET-1 and its receptors are different in human right and left ventricular endocardial endothelial cells. Peptides 2005; 26: 1427-35.
14. [14] Jacques D, Sader, S Perreault C, Abdel-Samad D, Jules F, Provost C. NPY, ET-1 and Ang II nuclear receptors in human endocardial endothelial cells. Can J Physiol Pharmacol 2006; 84(3-4): 299-307.
15. [15] Jacques D, Abdel-Samad D. Neuropeptide Y (NPY) and NPY receptors in the cardiovascular system: Implication in the regula-tion of intracellular calcium. Can J Physiol Pharmacol 2007; 85(1): 43-53.
16. [16] Abdel-Samad D, Perreault C, Ahmarani L, et al. Differences in neuropeptide Y-induced secretion of endothelin-1 in left and right human endocardial endothelial cells. Neuropeptides 2012;46(6): 373-82.
17. [17] Provost C, Choufani F, Avedanian L, Bkaily G, Gobeil F, Jacques D. Nitric oxide and reactive oxygen species in the nucleus revis-ited. Can J Physiol Pharmacol 2010; 88(3): 296-304.
18. [18] Goetzl EJ. Diverse pathways for nuclear signaling by G protein-coupled receptors and their ligands. FASEB J 2007; 21(3): 638-42.
19. [19] Ahmarani L, Avedanian L, Al-Khoury J, Perreault C, Jacques D, Bkaily G. Whole cell and nuclear NADPH oxidases levels and dis-tribution in human endocardial endothelial, vascular smooth mus-cle, and vascular endothelial cells. Can J Physiol Pharmacol 91: in press.
20. [20] Valdehita A, Bajo AM, Fernández-Martínez AB, et al. Nuclear localization of vasoactive intestinal peptide (VIP) receptors in hu-man breast cancer. Peptides 2010; 31(11): 2035-45.
21. [21] Re M, Pampillo M, Savard M, et al. The human gonadotropin releasing hormone type I receptor is a functional intracellular GPCR expressed on the nuclear membrane. PLoS One 2010; 8; 5(7): e11489.
22. [22] Zhu T, Gobeil F, Vazquez-Tello A, et al. Intracrine signaling through lipid mediators and their cognate nuclear G-protein-coupled receptors: a paradigm based on PGE2, PAF, and LPA1 re-ceptors. Can J Physiol Pharmacol 2006; 84(3-4): 377-91.
23. [23] Abrenica B, Gilchrist JS. Nucleoplasmic Ca2+ loading is regulated by mobilization of perinuclear Ca2+. Cell Calcium 2000; 28: 127-36.
24. [24] Abrenica B, Pierce GN, Gilchrist JS. Nucleoplasmic calcium regu-lation in rabbit aortic vascular smooth muscle cells. Can J Physiol Pharmacol 2003; 81: 301-10.
25. [25] Bkaily G, D'Orléans-Juste P, Pothier P, Calixto JB, Yunes R. Nu-clear membrane receptors and channels; potential therapeutical tar-gets for drug action. Drug Dev Res 1997; 42: 211-22.
26. [26] Bkaily G, Jacques D, Gobeil F Jr, Chemtob S, D'Orléans-Juste P. Nuclear membranes channels, exchangers and G-protein coupled receptors: a new target for drug action. Curr Topics Pharmacol 2003; 7: 269-78.
27. [27] Bkaily G, Jacques D, Pothier P. Use of confocal microscopy to investigate cell structure and function. Methods Enzymol 1999; 307: 119-35.
28. [28] Bkaily G, Massaad D, Choufani S, Jacques D, D’Orleans-Juste P. Role of endothelin-1 receptors in the sarcolemma membrane and the nuclear membrane in the modulation of basal cytosolic and nu-clear calcium levels in heart cells. Clin Sci (Lond) 2002; 103: 141S-47S.
29. [29] Bkaily G, Avedanian L, Jacques D. Nuclear membranes’ receptors and channels as targets for drug development in cardiovascular dis-eases. Can J Physiol Pharmacol 2009; 87: 108-19.
30. [30] Brunner F. Dependence of endothelin-1 secretion on Ca2+. Biochem Pharmacol 1995; 49: 1785-91.
31. [31] Naik RD, McNeill JR, Wilson TW, Gopalakrishnan V. Nuclear Ca2+ signaling to endothelin-1 in rat aortic smooth-muscle cells. J Car-diovasc Pharmacol 1998; 31(1): S199-S202.
32. [32] Booz GW, Conrad KM, Hess AL, Singer HA, Baker KM. Angio-tensin-II-binding sites on hepatocyte nuclei. Endocrinology 1992; 130: 3641-49.
33. [33] Tang SS, Rogg H, Schumacher R, Dzau VJ. Characterization of nuclear angiotensin-II-binding sites in rat liver and comparison with plasma membrane receptors. Endocrinology 1992; 131(1): 374-80.
34. [34] Lee DK, Lança AJ, Cheng R, et al. Agonist-independent nuclear localization of the Apelin, angiotensin AT1, and bradykinin B2 re-ceptors. J Biol Chem 2004; 279(9): 7901-8.
35. [35] Tadevosyan A, Maguy A, Villeneuve LR, et al. Nuclear-delimited angiotensin receptor-mediated signaling regulates cardiomyocyte gene expression. J Biol Chem 2010; 285(29): 22338-49.
36. [36] Bkaily G, Jaalouk D, Jacques D, et al. Bradykinin activates R-, T-, and L-type Ca2+ channels and induces a sustained increase of nu-clear Ca2+ in aortic vascular smooth muscle cells. Can J Physiol Pharmacol 1997; 75(6): 652-60.
37. [37] Savard M, Barbaz D, Bélanger S, et al. Expression of endogenous nuclear bradykinin B2 receptors mediating signaling in immediate early gene activation. J Cell Physiol 2008; 216: 234-44.
38. [38] Bhattacharya M, Peri, K, Ribeiro-da-Silva A, et al. Localization of functional prostaglandin E2 receptors EP3 and EP4 in the nuclear envelope. J Biol Chem 1999; 274(22): 15719-24.
39. [39] Jacques D, Sader S, Perreault C, et al. Presence of neuropeptide Y and Y1 receptor in the plasma membrane and nuclear envelope of human endocardial endothelial cells: modulation of intracellular calcium. Can J Physiol Pharmacol 2003; 81: 288-300.
40. [40] Avedanian L, Riopel J, Bkaily G, Nader M, D’Orleans-Juste P, Jacques D. ETA receptors are present in human aortic vascular en-dothelial cells and modulate intracellular calcium. Can J Physiol Pharmacol 2010; 88: 817-29.
41. [41] Bkaily G, Nader M, Avedanian L, et al. G -protein-coupled recep-tors, channels, and Na+-H+ exchanger in nuclear membranes of heart, hepatic, vascular endothelial, and smooth muscle cells. Can J Physiol Pharmacol 2006; 84(3-4): 431-41.
42. [42] Jacques D, Sader S, Choufani S, D'Orléans-Juste P, Charest D. Endothelin-1 regulates cytosolic and nuclear Ca2+ in human endo-cardial endothelium. J Cardiovasc Pharmacol 2000; 36: 397-400.
43. [43] Marrache AM, Gobeil F Jr, Bernier SG, et al. Proinflammatory gene induction by platelet-activating factor mediated via its cognate nuclear receptor. J Immunol 2002; 169(11): 6474-81.
44. [44] Gobeil F Jr, Bernier SG, Vazquez-Tello A, et al. Modulation of pro-inflammatory gene expression by nuclear lysophosphatidic acid receptor type-1. J Biol Chem 2003; 278(40): 38875-83.
45. [45] Takei Y, Takahashi K, Kanaho Y, Katada T. Possible involvement of a pertussis toxin-sensitive GTP-binding protein in protein trans-port into nuclei isolated from rat liver. J Biochem 1994; 115(3): 578-83.
46. [46] Saffitz JE, Nash JA, Green KG, Luke RA, Ransnas LA, Insel PA. Immunoelectron microscopic identification of cytoplasmic and nu-clear Gs alpha in S49 lymphoma cells. FASEB J 1994; 8(2): 252-8.
47. [47] Balboa MA, Insel PA. Nuclear phospholipase D in Madin-Darby canine kidney cells Guanosine 5'-O-(thiotriphosphate)-stimulated activation is mediated by RhoA and is downstream of protein kinase C. J Biol Chem 1995; 270(50): 29843-7.
48. [48] Hentze MW. Protein synthesis Believe it or not-translation in the nucleus. Science 2001; 293: 1058-59.
49. [49] Iborra FJ, Jackson DA, Cook PR. Coupled transcription and trans-lation within nuclei of mammalian cells. Science 2001; 293: 1139-42.
50. [50] D'Orléans-Juste P, Labonté J, Bkaily G, Choufani S, Plante M, Honoré JC. Function of the endothelin(B) receptor in cardiovascu-lar physiology and pathophysiology. Pharmacol Ther 2002; 95: 221-38.
51. [51] Chun M, Lin HY, Henis YI, Lodish HF. Endothelin-induced endo-cytosis of cell surface ETA receptors. Endothelin remains intact and bound to the ETA receptor. J Biol Chem 1995; 270(18): 10855-60.
52. [52] Paasche JD, Attramadal T, Sandberg C, Johansen HK, Attramadal H. Mechanisms of endothelin receptor subtype-specific targeting to distinct intracellular trafficking pathways. J Biol Chem 2001 6(36): 34041-50.
53. [53] Fricker M, Hollinshead M, White N, Vaux D. Interphase nuclei of many mammalian cell types contain deep, dynamic, tubular mem-brane-bound invagination of the nuclear envelope. Nat Cell Biol 1997; 5: 440-46.
54. [54] D'Orléans-Juste P, Plante M, Honoré JC, Carrier E, Labonté J. Synthesis and degradation of endothelin-1. Can J Physiol Pharmacol 2003; 81(6): 503-10.
55. [55] Rautureau Y, Schiffrin EL. Endothelin in hypertension: an update. Curr Opin Nephrol Hypertens 2012; 21: 128-36.
56. [56] Touyz RM. New insights into mechanisms of hypertension. Curr Opin Nephrol Hypertens 2012; 21: 119-21.
57. [57] Al-Khoury J, Bkaily G, Chahine M, Jacques D, D'Orléans-Juste P. ETB receptor dependent alteration in aortic responses to ET-1 in the cardiomyopathic hamster. Can J Physiol Pharmacol 2006; 84: 787-94.
58. [58] Jacques D, Abdel Malak NA, Sader S. Angiotensin II and its recep-tors in human endothelial endothelial cells: role in modulating in-tracellular calcium. Can J Physiol Pharmacol 2003; 81: 259-66.
59. [59] Chen R, Mukhin YV, Garnovskaya MN, et al. A functional angio-tensin II receptor-GFP fusion protein: evidence for agonist-dependent nuclear translocation. Am J Physiol 2000; 279: F440-48.
60. [60] Bruneval P, Hinglais N, Alhenc-Gelas F, et al. Angiotensin I con-verting enzyme in human intestine and kidney Ultrastructural im-munohistochemical localisation. Histochemistry 1986; 85: 73-80.
61. [61] Allen AM, Zhuo J, Mendelsohn FO. Localization and function of angiotensin II AT1 receptors. Am J Hypert 2000; 13: 31S-8S.
62. [62] Sun Y, Weber KT. Tissue angiotensin II and myocardial infarction In: M Karmazyn Ed. Myocardial ischemia: Mechanisms, reperfusion, protection. Basal, Birkhäuser Verlag: Germany 1996; pp. 479-88.
63. [63] Hein L, Stevens SE, Barsh GS, Pratt RE, Kobilka BK, Dzau VJ. Overexpression of Angiotensin AT1 receptor transgene in the mouse myocardium produces lethal phenotype associated with myocytes hyperplasia and heart block. Proc Natl Acad Sci USA 1997; 94: 6391-96.
64. [64] Lee YH, Mungunsukh O, Tutino RL, Marquez AP, Day RM. An-giotensin-II-induced apoptosis requires regulation of nucleolin and Bcl-xL by SHP-2 in primary lung endothelial cells. J Cell Sci 2010; 123: 1634-43.
65. [65] Herzog H, Hort YJ, Ball HJ, Hayes G, Shine J, Selbie LA. Cloned human neuropeptide Y receptor couples to two different second messenger systems. Proc Natl Acad Sci USA 1992; 89: 5794-98.
66. [66] Kassis S, Olasmaa M, Terenius L, Fishman PH. Neuropeptide Y inhibits cardiac adenylate cyclase through a pertussis toxin-sensitive G protein. J Biol Chem 1987; 262(8): 3429-31.
67. [67] Aakerlund L, Gether U, Fuhlendorff J, Schwartz TW, Thastrup O. Y1 receptors for neuropeptide Y are coupled to mobilization of in-tracellular calcium and inhibition of adenylate cyclase. FEBS Lett 1990; 260: 73-8.
68. [68] Zukowska-Grojec Z, Karmatowska-Prokopczuk E, Rose W, et al. Neuropeptide Y: a novel angiogenic factor from the sympathetic nerves and endothelium. Circ Res 1998; 83: 187-95.
69. [69] Zukowska-Grojec Z, Karwatowska-Prokopczuk E, Fischer TA, Ji H. Mechanisms of vascular growth effect of neuropeptide Y: role of its inducible receptors. Regul Pept 1998; 75-76: 231-38.
70. [70] Zukowska Z, Pons J, Lee EW, Li L. Neuropeptide Y: a new media-tor linking sympathetic nerves, blood vessels and immune system. Can J Physiol Pharmacol 2003; 81: 89-94.
71. [71] Shine J, Potter EK, Biden T, Selbie LA, Herzog H. Neuropeptide Y and regulation of the cardiovascular system. J Hyper 1994; 1210: S41-5.
72. [72] Jacques D, Sader S, Perreault C, Abdel-Samad D. NPY and NPY receptors: Presence distribution and roles in the regulation of the endocardial endothelium and cardiac function. EXS 2006; 95: 77-87.
73. [73] Abdel-Samad D, Jacques D, Perreault C, Provost S. NPY regulates human endocardial endothelial cell function. Peptides 2007; 28: 281-87.
74. [74] Rettig J, Neher E. Emerging roles of presynaptic proteins in Ca2+-trigged exocytosis. Science 2002; 298: 781-85.
75. [75] MacNeil DJ. NPY Y1 and Y5 receptor selective antagonists as anti-obesity drugs. Curr Top Med Chem 2007; 7(17): 1721-33.
76. [76] Gullestad L, Bjurø T, Aaberge L, et al. The effect of a neuropeptide Y Y1 receptor antagonist in patients with angina pectoris. Eur Heart J 2003; 24: 1120-27.
77. [77] Ihida K, Predescu D, Czekay RP, Palade GE. Platelet activating factor receptor (PAF-R) is found in a large endosomal compart-ment in human umbilical vein endothelial cells. J Cell Sci 1999; 112 (Pt 3): 285-95.
78. [78] Jockers R, Da Silva A, Strosberg AD, Bouvier M, Marullo S. New molecular and structural determinants involved in beta 2-adrenergic receptor desensitization and sequestration Delineation using chi-meric beta 3/beta 2-adrenergic receptors. J Biol Chem 1996; 271(16): 9355-62.